Article: 0258

Topic: FC10 - Free Communications 10: Psychosurgery and Stimulation Methods (ECT, TMS, VNS, DBS), Psychotherapy, Sexual Medicine and Mental Health, Women, Gender and Mental Health Count

Psychopharmacological Treatment with SNRis in Pregnancy: a Case-series with a Long-term Follow-up

L. Orsolini¹, C. Bellantuono¹

¹United Hospital and Academic Department of Experimental and Clinical Medicine, Università Politecnica delle Marche, Ancona, Italy

To date, very little data is available regarding the exposure to SNRIs during the pregnancy. A prospective cohort study was conducted on 6 pregnant women (W) in treatment with venlafaxine(V) or duloxetine(D), afferent to the Clinic of Affective Disorders in Pregnancy and Postpartum of the United Hospital of Ancona. A 2-years follow-up was conducted on short-/long-term neonatal outcomes. From 2010 to 2014 all W treated with V or D during pregnancy were selected, assessed by means of the SCID-I, the BPRS, the EPDS and the HAM-D and followed up to 2 years of age of the child. A semi-structured interview was conducted at 3,6,12 and 24 months from delivery. 4W were exposed to V(37.5-75 mg daily):1 case throughout pregnancy; 1 only during the first month; 2 in the late pregnancy. Only 1W developed a gestational diabetes(GD), spontaneously resolved after the delivery. 2W were exposed to D(30-60 mg daily) throughout their pregnancies: both W developed a GD at their eighth month of pregnancy. All pregnancies were regular, natural and full term. All newborns had normal APGAR scores and parameters. No MM or PC were reported after V or D exposure. None of the babies were breastfed. No health problems were reported during the follow-up period but 1 case of a decreased muscle tone with a delay in the deambulation, spontaneously resolved after the first year of age. Nevertheless, given the paucity of the studies so far published, it needs to deepen the potential role of V/D in the onset of GD.